A disposable sensor chip for biological component concentration measurement includes: a chip main body defining a cavity through which a body fluid is flowable; and a reagent located in the cavity such that the body fluid flowing through the cavity comes into contact with the reagent. The reagent comprises a 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt.

There is provided a kit that is used for fractionation of cholesterol (lipoprotein C) in a lipoprotein other than small dense LDL in a sample, the kit containing a first reagent composition having at least one activity selected from the group consisting of a cholesterol esterase activity and a cholesterol oxidase activity and a second reagent composition for quantifying the lipoprotein C of a measurement target, where a ratio R1 represented by ABS400/ABS450 is 0.90 or more and 3.50 or less, and in an absorption spectrum after storing the second reagent composition at 37° C. for two weeks, the ratio R1 represented by ABS400/ABS450 is 0.90 or more and 9.00 or less.

There is provided a kit that is used for fractionation of cholesterol (lipoprotein C) in a lipoprotein other than small dense LDL in a sample, the kit containing a first reagent composition having at least one activity selected from the group consisting of a cholesterol esterase activity and a cholesterol oxidase activity and a second reagent composition for quantifying the lipoprotein C of a measurement target, where a ratio R1 represented by ABS400/ABS450 is 0.90 or more and 3.50 or less, and in an absorption spectrum after storing the second reagent composition at 37° C. for two weeks, the ratio R1 represented by ABS400/ABS450 is 0.90 or more and 9.00 or less.

Disclosed is a method for measuring sterol in lipoprotein, comprising: forming a complex by contacting lipoprotein in a sample, a tagged sterol, and a first capture body that specifically binds to the tag and has a labeling substance with each other, the complex comprising the lipoprotein comprising the tagged sterol and the first capture body; and detecting a signal generated by the labeling substance comprised in the complex, wherein in the tagged sterol, the tag is added to C3 position of a sterol skeleton.

Disclosed is a method for measuring sterol in lipoprotein, comprising: forming a complex by contacting lipoprotein in a sample, a tagged sterol, and a first capture body that specifically binds to the tag and has a labeling substance with each other, the complex comprising the lipoprotein comprising the tagged sterol and the first capture body; and detecting a signal generated by the labeling substance comprised in the complex, wherein in the tagged sterol, the tag is added to C3 position of a sterol skeleton.

This invention provides a method for quantification of lipoprotein cholesterol in two steps using an autoanalyzer without pretreatment of an analyte, wherein spontaneous color development of a reagent during storage is suppressed, a kit for quantification used in the method, and a method for preparing such kit. The kit for quantification of lipoprotein cholesterol in a sample obtained from a subject used in the method for quantification of lipoprotein cholesterol in two steps comprises: (1) a first reagent composition comprising cholesterol esterase, cholesterol oxidase, cholesterol esterase, and cholesterol oxidase and leading lipoprotein cholesterol other than the analyte to the outside of the reaction system; and (2) a second reagent composition for quantifying the analyte lipoprotein cholesterol, wherein either the first reagent composition or the second reagent composition comprises at least a coupler, an iron complex, peroxidase, catalase, a hydrogen donor, and a surfactant, provided that the coupler and the hydrogen donor are not allowed to be present in the same reagent composition, and the coupler, the iron complex, and peroxidase are not allowed to be present together in either of the first reagent composition or the second reagent composition.

The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint. Step iii) may be carried out at any stage up to and including step iv) but before steps v) or vi). The reagent of step iii) may be applied to the sample separately or may be included in a reagent mixture during steps i) or iv). A corresponding kit is also provided.

The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint. Step iii) may be carried out at any stage up to and including step iv) but before steps v) or vi). The reagent of step iii) may be applied to the sample separately or may be included in a reagent mixture during steps i) or iv). A corresponding kit is also provided.

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.